bimatoprost sustained-release implant

Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
Standards of care in treating glaucomaAs technology and glaucoma care evolves, so must our treatment guidelines
Bimatoprost sustained-release implants: Potential new pathway for glaucoma patientsThe bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.
Sustained-release bimatoprost implant addresses challenges of adherencePhase I/II interim data for a bimatoprost sustained-release implant show the device has favorable safety and efficacy and may address the problem of patient nonadherence.